IMULAN BioTherapeutics Appoints Dr. Daniel Gingerich as Chief Scientific Officer
Dr. Craig Woods, CEO of IMULAN, stated, “We are fortunate to have Dr. Gingerich join the team. He brings a world of experience in clinical trial design, regulatory affairs, and immunology which will facilitate development of our new immune based treatments and biologics.”
Dr. Daniel Gingerich, added, “I am excited to be working with IMULAN on developing their first-in-class technologies for atopic dermatitis, feline stomatitis, dilated cardiomyopathy, and viral infections. We are hopeful that these new technologies will produce a new generation of more effective veterinary therapies while advancing our comparative disease programs.”
Before joining IMULAN, he was VP- Technical and Regulatory Affairs for Stolle Milk Biologics, Inc., VP-Pharmaceutical Research at Fort Dodge Laboratories (Wyeth), Dir. of Animal Health Research-Bristol Myers Animal Health, and Section Head-Pharmacology and Toxicology at Pitman Moore, Inc. (Johnson & Johnson). Prior to industry Dan was an Asst. Professor, Food Animal Medicine and Surgery at The Ohio State University College of Veterinary Medicine. Dan has published a variety of papers in the areas of immunology, orthopedics, and pharmacology. Dan obtained his B.S. and D.V.M. from the University of Minnesota, and completed his M.S. (pharmacology) and residency in large animal medicine from the Ohio State University.
About Imulan: Imulan develops unique, precision immune regulating compounds for veterinary medicine. Imulan has several platforms for small and large animal medicine with a primary focus on biological strategies for infectious, autoimmune, and immune mediated diseases. IMULAN launched Lymphocyte T-Cell Immunomodulator in 2008, the first approved treatment aid in the United States for Feline Leukemia Virus and Feline Immunodeficiency Virus infections. For more information about Imulan, please visit www.imulan.com.